A total of $500,000 per year in Developmental Funds is requested in this application for: 1) Pilot Projects;2)New Investigators / Recruitment, and 3) Developing Shared Resources. Developmental Funds represent the financial foundation of growth and development of the Center. The CCSG is leveraged with other institutional sources to create a total investment pool toward new scientists, resources and science. During the past grant period, a total of $4,596,819 were invested in pilot projects, new investigators and shared resources. Of this amount, $1,417,500 came from CCSG Developmental Funds, and $3,179,319 was provided from other Cancer Center funds. The current return on investment is $10,953,939;a 138% ROI. Of the $1,417,500 in CCSG funds, $668.000 was invested in pilot projects. Extramural grants obtained as a result of those pilot projects amount to $5,069,686;a 6-fold return. Extramural grants obtained by those recipients, although not necessarily directly resulting from pilot project data, amount to $25,641,499. CCSG funds invested in Recruitment/New Investigators amount to $672.500 (plus $2,302,349 in other funds). That CCSG investment has returned $7,134,253, an ROI of 961%. While the future investments are described, and should be viewed in relation to the overall strategic plans of the Center, equally important are the systems employed to identify needs and the decision-making process that is in place regarding funding allocations. Recruitment and new investigator pursuits generally follows a structured analysis that includes: 1) input from program and senior leaders and;2) identifying the priority level and available financial resources. For example, the 2004 Strategic Plan concludes that a greater number of clinical scientists are needed;those both grounded in clinical research and those with joint laboratory and clinical interests. The Plan notes the intention to further expand and link the Cancer Center with the physical sciences, including informatics and engineering. Discussions followed with program and senior leadership, then to discussion and negotiation with academic department chairs in order to determine the departmental positions and resources available for such appointments. This was followed by formation of a search committee. Such was the path followed for the recruitments of Tony Reid, MD, PhD, Gregory Daniels, MD, PhD and Catriona Jamieson, MD, PhD, the promising new translational research scientists that have joined the Moores Cancer Center. Pilot projects are employed to actualize other parts of the plan for the Center;i.e., mentoring our more junior clinical scientists and developing translational research projects with clinical endpoints. These objectives come to life with two recently implemented pilot project competitions - the Mentored Translational Research Award program and the Collaborative Translational Research Award program, fully described below. The programs are announced annually to the Cancer Center membership at six month intervals, with robust competition and selection in NIH multi-tiered review fashion. Pilot project funding from the CCSG is also matched by other funds in the Cancer Center. Joint recruitment between the Center and the Department of Bioengineering, including the allocation of an FTE, is ongoing for an accomplished cancer bioengineering scientist. Through the use of campus start-up funding and 3 assigned FTEs, Nicholas Schork, PhD, a UCSD professor of psychiatry specializing in bioinformatics, was recruited in 2005 as a new investigator and leader of our bioinformatics program. No CCSG funds were required for his recruitment, although the CCSG may be allocated to the further growth of this key area. Developing technologies and shared resources is ongoing with new scientific directions, needs assessment through periodic member surveys, and leadership determination of optimal support services. Over this past project period we have invested in technologies targeted at improved analysis of genomics data. Future services have been given serious consideration by Cancer Center members and leaders alike, with proposed CCSG allocations for three developing facilities closely mirroring the programmatic priorities of the Center.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA023100-27S9
Application #
8653400
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2011-05-01
Budget End
2013-04-30
Support Year
27
Fiscal Year
2013
Total Cost
$297,068
Indirect Cost
$102,566
Name
University of California San Diego
Department
Type
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Sen, Supriya; Langiewicz, Magda; Jumaa, Hassan et al. (2015) Deletion of serine/arginine-rich splicing factor 3 in hepatocytes predisposes to hepatocellular carcinoma in mice. Hepatology 61:171-83
Hoffmann, Hanne M; Tamrazian, Anika; Xie, Huimin et al. (2014) Heterozygous deletion of ventral anterior homeobox (vax1) causes subfertility in mice. Endocrinology 155:4043-53
Hartman, Lisa L R; Crawford, John R; Makale, Milan T et al. (2014) Pediatric phase II trials of poly-ICLC in the management of newly diagnosed and recurrent brain tumors. J Pediatr Hematol Oncol 36:451-7
Williams, Richard T; Barnhill, Lisa M; Kuo, Huan-Hsien et al. (2014) Chimeras of p14ARF and p16: functional hybrids with the ability to arrest growth. PLoS One 9:e88219
Huang, Carlos P; Fofana, Mariama; Chan, Jefferson et al. (2014) Copper transporter 2 regulates intracellular copper and sensitivity to cisplatin. Metallomics 6:654-61
Paolini, Paul; Pick, Daniel; Lapira, Jennifer et al. (2014) Developmental and extracellular matrix-remodeling processes in rosiglitazone-exposed neonatal rat cardiomyocytes. Pharmacogenomics 15:759-74
Goellner, Eva M; Smith, Catherine E; Campbell, Christopher S et al. (2014) PCNA and Msh2-Msh6 activate an Mlh1-Pms1 endonuclease pathway required for Exo1-independent mismatch repair. Mol Cell 55:291-304
Glidewell-Kenney, Christine A; Trang, Crystal; Shao, Paul P et al. (2014) Neurokinin B induces c-fos transcription via protein kinase C and activation of serum response factor and Elk-1 in immortalized GnRH neurons. Endocrinology 155:3909-19
Jiang, P; Mukthavaram, R; Chao, Y et al. (2014) In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cells. Br J Cancer 111:1562-71
Jacques, Bonnie E; Montgomery 4th, William H; Uribe, Phillip M et al. (2014) The role of Wnt/*-catenin signaling in proliferation and regeneration of the developing basilar papilla and lateral line. Dev Neurobiol 74:438-56

Showing the most recent 10 out of 359 publications